CD4 and tuberculosis: After adjusting for age and CD4 at TB diagnosis, sex, site of TB (pulmonary only or any extrapulmonary), timing of ART, and year of TB diagnosis, the multivariable analysis that was not stratified by study site continued to demonstrate a reduction in mortality risk among persons who received TB treatment 5–7 days/week in the continuation phase (HR = 0.75, 95% confidence interval [CI] 0.55–1.01, p = 0.06) (Table 2).